CN101990538A - c-MET蛋白激酶抑制剂 - Google Patents

c-MET蛋白激酶抑制剂 Download PDF

Info

Publication number
CN101990538A
CN101990538A CN2008801170093A CN200880117009A CN101990538A CN 101990538 A CN101990538 A CN 101990538A CN 2008801170093 A CN2008801170093 A CN 2008801170093A CN 200880117009 A CN200880117009 A CN 200880117009A CN 101990538 A CN101990538 A CN 101990538A
Authority
CN
China
Prior art keywords
compound
aliphatic group
solution
acceptable salt
add
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801170093A
Other languages
English (en)
Chinese (zh)
Inventor
D·劳弗
李磐
N·瓦尔
K·麦金蒂
Q·唐
S·隆金
L·法莫
D·沙农
D·雅各布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101990538A publication Critical patent/CN101990538A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN2008801170093A 2007-10-03 2008-09-30 c-MET蛋白激酶抑制剂 Pending CN101990538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97730507P 2007-10-03 2007-10-03
US60/977,305 2007-10-03
PCT/US2008/078239 WO2009045992A2 (en) 2007-10-03 2008-09-30 C-met protein kinase inhibitors

Publications (1)

Publication Number Publication Date
CN101990538A true CN101990538A (zh) 2011-03-23

Family

ID=40512401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801170093A Pending CN101990538A (zh) 2007-10-03 2008-09-30 c-MET蛋白激酶抑制剂

Country Status (12)

Country Link
US (1) US8481524B2 (enExample)
EP (1) EP2205589B1 (enExample)
JP (1) JP2010540649A (enExample)
CN (1) CN101990538A (enExample)
AT (1) ATE502935T1 (enExample)
AU (1) AU2008308900A1 (enExample)
CA (1) CA2701124A1 (enExample)
DE (1) DE602008005786D1 (enExample)
ES (1) ES2361650T3 (enExample)
MX (1) MX2010003563A (enExample)
NZ (1) NZ584311A (enExample)
WO (1) WO2009045992A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242216A (zh) * 2013-05-07 2013-08-14 兰州梦唐精细化工有限公司 N- Boc -六氢-5-氧代环戊[C]并吡咯的合成方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004188A (es) 2008-10-21 2011-06-09 Vertex Pharma Inhibidores de la proteina cinasa c-met.
KR20120112755A (ko) 2010-01-07 2012-10-11 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 복소환 화합물
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2014103947A1 (ja) 2012-12-25 2014-07-03 日本曹達株式会社 ハロゲン化アニリンおよびその製造方法
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6660060B2 (ja) 2014-09-16 2020-03-04 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697352B1 (en) * 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
US7169781B2 (en) * 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242216A (zh) * 2013-05-07 2013-08-14 兰州梦唐精细化工有限公司 N- Boc -六氢-5-氧代环戊[C]并吡咯的合成方法

Also Published As

Publication number Publication date
ATE502935T1 (de) 2011-04-15
WO2009045992A2 (en) 2009-04-09
NZ584311A (en) 2012-03-30
CA2701124A1 (en) 2009-04-09
US8481524B2 (en) 2013-07-09
JP2010540649A (ja) 2010-12-24
WO2009045992A3 (en) 2009-06-04
US20110136789A1 (en) 2011-06-09
EP2205589B1 (en) 2011-03-23
ES2361650T3 (es) 2011-06-21
MX2010003563A (es) 2010-06-02
AU2008308900A1 (en) 2009-04-09
DE602008005786D1 (de) 2011-05-05
EP2205589A2 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
CN101479255B (zh) 用于治疗增殖性病症的c-MET蛋白激酶抑制剂
CN101990538A (zh) c-MET蛋白激酶抑制剂
ES2388883T3 (es) Derivados de pirimidinil-piridazinona
CN104870448B (zh) 三唑并吡嗪
ES2559427T3 (es) Derivados de azaindol
ES2819867T3 (es) Pirimidinas condensadas como inhibidores del complejo p97
ES2313991T3 (es) Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
ES2394147T3 (es) Derivados de piridazinona
JP6424224B2 (ja) 新規ビスアミドピリジン
AU2014294866B2 (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
PT2421825E (pt) Azetidinil diamidas enquanto inibidoras da lipase de monoacilglicerol
CN102317277A (zh) C-met蛋白激酶抑制剂
TW201043635A (en) New compounds 745
JP2016515561A (ja) Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体
PT821685E (pt) Derivados de indolo-3-carbonilo e indolo-3-sulfonilo como anatagonistas do factor activador de plaquetas
CN111440164B (zh) 6-炔基-吡啶衍生物
CN102448968A (zh) C-met蛋白激酶的取代的吡唑抑制剂
CN102459283A (zh) C-met 蛋白激酶的氨基吡唑三唑并噻二唑抑制剂
MX2010012804A (es) Derivados de dihidropirazol como moduladores de tirosina cinasa para el tratamiento de tumores.
HK1151519A (en) C-met protein kinase inhibitors
TW202504610A (zh) 吡唑并嘧啶酮化合物
HK1161257A (en) C-met protein kinase inhibitors
HK1129890B (en) C-met protein kinase inhibitors for the treatment of proliferative disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151519

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110323

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1151519

Country of ref document: HK